ClinicalTrials.gg
RecruitingNCT07608432FORZETTOUpdated May 27, 2026

Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)

A Phase 3 interventional study of Zeleciment Rostudirsen (DYNE-251) and Placebo in Duchenne Muscular Dystrophy (DMD), Muscular Dystrophy, Duchenne and Muscular Dystrophy (DMD), sponsored by Dyne Therapeutics. Recruiting at 1 site in United States. Open to male participants aged 4 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-05-27.

Sponsored by Dyne Therapeutics · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
4 Years to 18 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 233 studies in Muscular Dystrophy, Duchenne with a site in United States — 35 open to participants now, 60 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · United States.

Planned enrollment
34th of 172
90 · median 25
Started
2026
with 8 others
Phase 3
32 of 233
3 open now
Primary completion
2030-12
later than 50 of 59 live
Registered
229th of 233
by date

Among the 233 studies in Muscular Dystrophy, Duchenne with a site in United States, this one is the 34th largest by planned enrollment of the 172 interventional ones that give a count, is one of 9 that started in 2026, is one of 32 in phase 3, reaches primary completion later than 50 of the 59 other live ones, and was the 229th registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

35 of the 233 studies in Muscular Dystrophy, Duchenne with a site in United States are open now. Recruiting first, the newest first:

29 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: 4 Years to 18 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 233 studies in Muscular Dystrophy, Duchenne with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to assess the efficacy, safety, and tolerability of zeleciment rostudirsen (DYNE-251) administered intravenously (IV) every 4 weeks to ambulatory Duchenne muscular dystrophy (DMD) participants, 4 to 18 years of age, with dystrophin mutations amenable to exon 51 skipping.

Read the detailed description

The study consists of three periods: a Screening period (up to 6 weeks), a Placebo-Controlled Period (72 weeks) and an open-label Long-Term Extension Period (96 weeks).

03

Conditions studied

  • Duchenne Muscular Dystrophy (DMD)
  • Muscular Dystrophy, Duchenne
  • Muscular Dystrophy (DMD)
  • DMD
  • Muscular Dystrophies
  • Muscular Dystrophy in Children
  • Muscular Dystrophy, Duchenne Type
  • Muscular Dystrophy, Duchenne and Becker Types
  • Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy)
  • Genetic Disease, Inborn
  • Genetic Disease, X-Linked
  • Congenital, Hereditary, and Neonatal Diseases and Abnormalities
  • Neuromuscular Diseases (NMD)

Keywords

  • Ambulatory
  • DMD
  • Duchenne Muscular Dystrophy
  • Duchenne
  • Dyne
  • Dyne Therapeutics
  • DYNE-251
  • Dystrophy
  • Exon Skipping
  • Exon 51
  • FORZETTO
  • Pediatric
  • PMO
  • Muscle Function
  • Muscular Dystropy, Duchenne
  • Rise From Floor
  • RFF
  • RFF Velocity
  • Rostudirsen
  • Time to rise
  • TTR
  • TTR Velocity
  • Zeleciment rostudirsen
  • Z-rostudirsen
04

Who can participate

Ages eligible
4 Years to 18 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ambulatory male with confirmed diagnosis of DMD and with a mutation in the dystrophin gene characterized by exon deletion amenable to exon 51 skipping .
  • Rise From Floor (RFF) time must be \< 10 seconds for both screening assessments .
  • Receiving a stable daily or weekend dosage of for at least 24 weeks prior to randomization with the expectation of maintaining a stable dose during the Placebo-Controlled Period of the study (unless dose adjustment is required by weight change)

Exclusion criteria

Exclusion Criteria:

  • Receipt of ongoing therapy (other than ) within 12 weeks prior to randomization
  • Use of any pharmacologic treatment (other than glucocorticoids) that may have an effect on muscle strength or function within 12 weeks prior to randomization
  • Any change in prophylaxis/treatment for congestive heart failure (CHF) within 12 weeks prior to randomization
  • Receipt of eteplirsen within 1 week prior to randomization
  • Receipt of alternative exon-skipping or dystrophin-modifying therapy or zeleciment rostudirsen within 24 weeks prior to randomization
  • Receipt of givinostat within 12 weeks prior to randomization
  • Receipt of gene therapy at any time

Note: Other inclusion or exclusion criteria may apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Placebo-Controlled Period: Zeleciment Rostudirsen (DYNE-251)

    Participants will be randomized to receive zeleciment rostudirsen, once every 4 weeks (Q4W) for up to 72 weeks.

    Drug: Zeleciment Rostudirsen (DYNE-251)

  • Placebo comparator
    Placebo-Controlled Period: Placebo

    Participants will be randomized to receive placebo, Q4W for up to 72 weeks.

    Drug: Placebo

  • Experimental
    Open-Label Long-Term Extension Period: Zeleciment Rostudirsen (DYNE-251)

    All participants who complete the Placebo-Controlled Period of the study will receive zeleciment rostudirsen administered Q4W for up to 96 weeks.

    Drug: Zeleciment Rostudirsen (DYNE-251)

Interventions

  • DrugZeleciment Rostudirsen (DYNE-251)

    Administered by IV infusion

  • DrugPlacebo

    Administered by IV infusion

06

What researchers measure

Primary outcomes

  1. Rise From Floor (RFF) velocity

    Time frame: Baseline, Week 73

Secondary outcomes

  1. RFF (Rise From Floor) velocity

    Time frame: Baseline, up to Week 169

  2. Stride Velocity 95th Percentile (SV95C)

    Time frame: Baseline, Week 73, up to Week 169

  3. North Star Ambulatory Assessment (NSAA) Total Score

    Time frame: Baseline, Week 73, up to Week 169

  4. 10-Meter Walk/Run (10MWR) Velocity

    Time frame: Baseline, Week 73, up to Week 169

  5. 4-Stair Climb (4SC) velocity

    Time frame: Baseline, Week 73, up to Week 169

  6. Functional Composite score

    Time frame: Baseline, Week 73, up to Week 169

  7. Forced Vital Capacity (FVC)

    Time frame: Baseline, Week 73, up to Week 169

  8. Patient Global Impression of Severity (PGI-S)

    Time frame: Baseline, Week 73, up to Week 169

  9. Outcome of Patient Global Impression of Change (PGI-C)

    Time frame: Week 73, up to Week 169

  10. Blood Creatine Kinase (CK) levels

    Time frame: Baseline, Week 73, up to Week 169

  11. Incidence of participants With Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Through study completion, up to Week 173

  12. Maximum Observed Plasma Drug Concentration of DYNE-251 (Cmax)

    Time frame: Through study completion, up to Week 169

  13. Time to Maximum Observed Plasma Drug Concentration of DYNE-251 (tmax)

    Time frame: Through study completion, up to Week 169

  14. Area Under the Plasma Drug Concentration-Time Curve From Time 0 to the Last Quantifiable Concentration of DYNE-251 in Plasma (AUC-tlast)

    Time frame: Through study completion, up to Week 169

  15. Area Under the Plasma Drug Concentration Versus Time Curve From Time 0 (Dosing) Extrapolated to Time Infinity of DYNE-251 (AUC∞)

    Time frame: Through study completion, up to Week 169

  16. Apparent Terminal Phase Elimination Rate Constant of DYNE-251 in Plasma (λz)

    Time frame: Through study completion, up to Week 169

  17. Apparent Terminal Elimination Half-Life of DYNE-251 in Plasma (t½)

    Time frame: Through study completion, up to Week 169

  18. Total Body Clearance (CL) of DYNE-251

    Time frame: Through study completion, up to Week 169

  19. Volume of Distribution at the Terminal Phase of DYNE-251 in Plasma (Vz)

    Time frame: Through study completion, up to Week 169

  20. Volume of Distribution at Steady State of DYNE-251 in Plasma (Vss)

    Time frame: Through study completion, up to Week 169

  21. Incidence of Participants With Antidrug Antibodies (ADAs)

    Time frame: Through study completion, up to Week 169

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Dec 2030, 54 months later.

Of 26 phase 3 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 73. This study's planned 54 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2026
First posted
May 27, 2026
StartEst.
Jun 2026
Primary completionEst.
Dec 2030
CompletionEst.
Oct 2032
Last update
May 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07608432
Lead sponsor
Dyne Therapeutics
Responsible party
Sponsor
First posted
May 27, 2026
Start date
Jun 2026 (estimated)
Primary completion
Dec 2030 (estimated)
Completion
Oct 2032 (estimated)
Last update
May 27, 2026

Study contacts

Dyne Clinical Trials
Contact
clinicaltrials@dyne-tx.com
+1-781-317-1919

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion